After suboptimal Phase II readout, Vertex looks to learn from experience as it optimizes next-generation AAT products

It may take Vertex longer to optimize its AAT therapy than it expected, but this time, the biotech can apply lessons learned from its similar experience developing cystic fibrosis therapies.

Although new results from a Phase II trial showed that AAT gene corrector VX-864 from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) failed to produce an effect that would drive clinical benefit, company management made the case that the study will inform decisions around a next-generation molecule that can reach the clinic next year...